PDCD1 and Hodgkins lymphoma: Initially approved for the treatment of classical Hodgkin’s lymphoma, sintilimab is a fully humanized IgG4 monoclonal antibody that binds PD-1 to block the interaction between PD-1 and its ligands (29).